Moreover, in a subset of patients with triple-negative breast cancer (TNBC), IFIT1 positivity was found to correlate with improved LRFS and DFS at 10 years, suggesting that IFIT1 may serve as a biomarker for treatment stratification [31]. The gene discussed is IFIT1; the disease is triple-negative breast carcinoma.